AnswersNow

AnswersNow Competitive Intelligence & Landscape

getanswersnow.com ·

Overview

AnswersNow Overview

AnswersNow is a private company specializing in virtual Applied Behavior Analysis (ABA) therapy services, primarily targeting families dealing with autism. Founded in 2017 and headquartered in Richmond, Virginia, the company aims to make autism support accessible everywhere through its innovative virtual platform (getanswersnow.com). Its core services include personalized, evidence-based ABA therapy delivered remotely, allowing families to access high-quality care without waitlists and with coverage from all major insurance carriers, including Medicaid (growjo.com).

With a workforce of around 102 employees and a recent funding round of $40 million in 2026, AnswersNow has experienced significant growth, expanding its team by 33% annually. The company's mission is to empower families and individuals with autism by providing flexible, accessible, and effective support, ultimately aiming to broaden opportunities for those on the spectrum (growjo.com). Its target market includes families seeking virtual autism therapy, healthcare providers, and insurance companies, positioning itself as a leader in telemedicine and autism support services (getanswersnow.com).

AnswersNow

AnswersNow Weekly Intel Updates

Receive weekly intel updates about AnswersNow straight to your inbox.

Competitors

AnswersNow Competitors

Roads to Recovery is a notable competitor in the social services sector, focusing on mental health and recovery programs. Its key differentiator is its specialized approach to mental health recovery, targeting a specific niche within social services. Compared to AnswersNow, which offers broader behavioral health solutions, Roads to Recovery emphasizes personalized recovery plans and community-based support, positioning itself as a leader in mental health recovery services (Growjo). Its market share remains smaller but is growing steadily within niche markets.

America World Adoption operates primarily in the adoption and family services space, offering support for international and domestic adoptions. Its market positioning is centered on family-centered care and comprehensive adoption services. Unlike AnswersNow, which provides behavioral health therapy, America World Adoption focuses on family integration and post-adoption support, with a pricing model tailored to long-term family services rather than direct therapy sessions (Growjo). Its market share is significant in the adoption sector but less directly competitive.

Northern Virginia Family Service (NVFS) provides a wide range of social services including mental health, housing, and family support. Its key differentiator is its extensive service network and community integration efforts, making it a broad-based social services provider. Compared to AnswersNow, NVFS offers more comprehensive, in-person services across multiple domains, whereas AnswersNow specializes in telehealth behavioral therapy, giving it a competitive edge in digital service delivery and scalability (Growjo).

In terms of market positioning, AnswersNow stands out with its focus on telehealth behavioral therapy, leveraging technology to reach a wider audience at potentially lower costs. While competitors like Roads to Recovery and NVFS focus on in-person and community-based services, AnswersNow’s digital-first approach allows for greater scalability and accessibility, especially in underserved areas. Pricing strategies vary, with AnswersNow offering subscription-based telehealth services, positioning itself competitively in the digital health market (Growjo). Overall, AnswersNow's market share is growing as telehealth adoption increases, but it faces competition from established social service providers expanding into digital solutions.

Product & Pricing

AnswersNow Product and Pricing Intelligence

AnswersNow offers a tiered research and data analysis platform with both free and paid plans. Its free plan allows users to access basic paper summaries, change citations into over 2000 formats, and search across more than 250 million research papers, receiving 5 credits per month (AnswerThis Pricing). The premium plan, billed annually at $21, provides unlimited searches and references, detailed citation features, data export options, and integration with reference management tools like Mendeley and Zotero, suitable for individual researchers or teams (AnswerThis Pricing).

Recent updates indicate that the platform continues to emphasize affordability and accessibility, with a focus on AI-powered research tools. The pricing structure has been designed to encourage annual subscriptions with a 40% savings, and the free tier remains available for passionate researchers and enterprise users (AnswerThis Pricing).

Overall, AnswersNow's product offerings balance free access to essential research tools with a paid tier that unlocks advanced features, supporting both individual and team-based research needs in a cost-effective manner.

Ad Campaigns

AnswersNow Ad Campaigns

AnswersNow is currently running 36 ads across Google — 36 on Google. Explore AnswersNow's live ad creative, messaging, and the platforms they advertise on in the ad library — updated automatically by ForesightIQ.

See of AnswersNow's ads

View ads

Hiring & Layoffs

AnswersNow Hiring and Layoffs

As of April 2026, AnswersNow is experiencing a period of active growth, highlighted by its recent completion of a $40 million Series B funding round in January 2026. This funding aims to expand its team, particularly doubling its clinical staff, and to roll out new service offerings, signaling a strategic focus on scaling its AI-enabled, BCBA-driven autism therapy platform (globenewswire). Despite this growth, there are no reports of layoffs at AnswersNow, and their hiring pattern suggests a focus on increasing capacity and technological innovation rather than workforce reduction (globenewswire).

In contrast, the broader tech industry is experiencing significant layoffs driven by AI and automation investments. For instance, Dell Technologies announced it would cut 11,000 jobs in 2026 as part of a strategic shift towards AI spending and efficiency improvements (laffaz). Similarly, Atlassian laid off approximately 10% of its workforce (around 1,600 employees) in March 2026, citing the need to adapt to AI-driven changes and to fund further investments in AI and enterprise sales (thenextweb). These layoffs reflect a broader industry trend where companies are restructuring to prioritize AI, often resulting in workforce reductions but also in strategic hiring in specialized AI roles (opentools.ai).

Meanwhile, OpenAI stands out with its aggressive hiring strategy, planning to nearly double its workforce from 4,500 to 8,000 employees by the end of 2026. This expansion, involving over 3,500 new jobs, is driven by competition with firms like Anthropic and aims to accelerate AI product development and enterprise adoption (metaintro). This hiring surge signals a strategic focus on growth and innovation in AI, contrasting with the layoffs seen elsewhere in the tech sector (technoingg). Overall, AnswersNow’s growth pattern indicates a focus on expanding specialized services through technological innovation, while broader industry trends show a mix of layoffs and aggressive hiring in AI to reshape company strategies.

Leadership

AnswersNow Management and Leadership Team

The leadership team at AnswersNow is composed of key executives who oversee various strategic and operational functions. Notable members include Adam Dreyfus, Chief Science Officer; Brian Hamilton, COO; Brittany Wierzba, Chief Research Officer; Jennifer Grasso, Chief Product Officer; Morry Belkin, CTO; and Jeff Beck, Co-Founder and CEO (The Org).

Jeff Beck, a co-founder, has been leading the company since its inception in 2016 and has a background in social work, emphasizing accessibility and clinical care (Jeff Beck profile). Morry Belkin, appointed as CTO in early 2026, brings extensive experience in technology leadership, with a background from Carnegie Mellon University (Equilar).

Recent leadership developments include the appointment of Morry Belkin as CTO in 2026, reflecting the company's focus on technological innovation. The company also announced the launch of a corporate advisory board in mid-2025 to support its growth and scaling efforts (Recent news). Overall, AnswersNow's leadership is focused on advancing its mission to provide accessible, evidence-based autism therapy through innovative virtual platforms.

Financials

AnswersNow Financial Performance, Fundraising, M&A

AnswersNow has demonstrated significant financial growth through recent funding rounds. In January 2026, the company completed a $40 million Series B funding round led by HealthQuest Capital, with participation from existing investors such as Left Lane Capital and Owl Ventures (Yahoo Finance). This funding will be used to scale operations, including doubling its clinical staff and expanding service offerings (Hit Consultant). The company's revenue as of 2018 was estimated to be between $1 million and $1.2 million, indicating modest revenue growth over recent years (Tracxn). Overall, AnswersNow's financial health appears strong, supported by its successful funding rounds and strategic investments aimed at expanding its telehealth autism therapy platform.

Partnerships

AnswersNow Partnerships, Clients and Vendors

AnswersNow has established itself as a rapidly growing leader in virtual ABA therapy for autism, with notable partnerships, significant funding, and a broad ecosystem of integrations. In 2021, AnswersNow partnered with Healthie, a comprehensive healthcare platform, to build a scalable telehealth infrastructure that supports nationwide delivery of ABA therapy, integrating various clinical and practice management tools (gethealthie.com). This partnership highlights their focus on leveraging technology to expand access and improve care delivery (gethealthie.com).

In 2026, AnswersNow secured its largest funding round to date, raising $40 million led by HealthQuest Capital, with participation from existing investors such as Left Lane Capital and Owl Ventures. This capital will enable AnswersNow to scale its AI-driven autism therapy model, doubling its clinical staff and expanding its service offerings (BriefGlance.com). Their recent funding success underscores their ecosystem's strength and investor confidence in their innovative approach (grpva.com).

Furthermore, AnswersNow maintains strategic relationships with key industry players and is actively expanding its ecosystem through partnerships and integrations. Their collaboration with ServiceNow, for example, involves leveraging the Now Platform to power their internal operations and training centers, further embedding them within a broader digital ecosystem (servicenow.com). These ecosystem relationships enable AnswersNow to enhance its technological capabilities and extend its reach in the healthcare sector.

Events

AnswersNow Event Participations

AnswersNow actively participates in various industry events to promote its virtual ABA therapy services and connect with healthcare professionals and families. Notably, they have been involved in major conferences such as the NACAC West Coast college fairs, where they engaged with over 10,000 high school students, showcasing their innovative tools and personalized education solutions (Answer.AI). Additionally, the company has been featured in prominent health and technology events like the HLTH conference, where they announced their $40 million Series B funding round aimed at scaling their AI-enabled, BCBA-led autism therapy platform (hlth.com). While specific details about other conferences, trade shows, webinars, or community events they sponsor, attend, or host are not explicitly listed in the search results, their active presence at major industry gatherings underscores their commitment to advancing autism care through virtual platforms.

Frequently Asked Questions

What does AnswersNow's decision to double clinical staff following its $40M Series B signal about where it sees its growth constraint?

AnswersNow is signaling that its primary bottleneck is BCBA (Board Certified Behavior Analyst) capacity, not technology or capital. The January 2026 Series B, led by HealthQuest Capital with participation from Left Lane Capital and Owl Ventures, is explicitly earmarked for doubling clinical staff alongside expanding service offerings — suggesting the company believes it has validated its virtual ABA model and is now in a supply-scaling phase rather than a product-discovery phase.

What does AnswersNow's 33% annual headcount growth rate, against a current base of roughly 102 employees, imply about its operational maturity ahead of a potential exit or Series C?

At roughly 102 employees growing 33% annually, AnswersNow is still in an early scaling stage where the organization is not yet large enough to have the operational redundancy or management layers typical of a Series C or pre-exit company. The simultaneous appointment of a CTO (Morry Belkin, early 2026) and the launch of a corporate advisory board (mid-2025) suggest leadership is actively building institutional infrastructure to match its capital raise, but the company is likely 18–36 months away from the organizational maturity that would support a large strategic transaction.

What does the appointment of Morry Belkin as CTO in early 2026 signal about AnswersNow's product direction?

Bringing in a dedicated CTO immediately after closing a $40M Series B strongly signals that AnswersNow is transitioning from a clinically led, tech-enabled model to one where AI and platform architecture are first-order strategic priorities. Prior to Belkin's appointment, the CTO role was either vacant or not publicly prominent; adding it now, alongside a Chief Product Officer (Jennifer Grasso) and a Chief Research Officer (Brittany Wierzba), indicates the company is assembling a product and engineering leadership layer capable of building proprietary AI systems rather than relying solely on third-party infrastructure.

What does AnswersNow's 2021 partnership with Healthie reveal about its build-vs-buy philosophy, and has that philosophy shifted?

The 2021 Healthie partnership — in which AnswersNow adopted Healthie's API to power scheduling, coaching, and clinical management — indicates that early on the company chose to buy or partner for core infrastructure rather than build it. The 2026 CTO hire and the framing of the Series B around AI-enabled therapy suggest the company is now shifting toward building more proprietary technology in-house, consistent with a maturation path where differentiated IP becomes critical for defensibility and valuation.

What does AnswersNow's insurance coverage positioning — accepting all major carriers including Medicaid — signal about its go-to-market strategy versus typical telehealth startups?

Accepting Medicaid alongside commercial insurance is a deliberate under-served-market play that most venture-backed telehealth startups avoid due to lower reimbursement rates and administrative complexity. This positions AnswersNow to capture demand in lower-income and rural populations where autism waitlists are longest, giving it a volume and mission-driven narrative that is attractive to healthcare-focused investors like HealthQuest Capital while also creating a competitive moat that pure-premium-market competitors cannot easily replicate.

Is AnswersNow's financial trajectory a credible growth story or does the gap between its ~$1–1.2M 2018 revenue estimate and its 2026 $40M raise raise red flags about capital efficiency?

The 2018 revenue estimate of $1–1.2M is now roughly eight years old and should not be used as a reliable current revenue proxy; the company has since raised a $40M Series B with participation from institutional healthcare investors including HealthQuest Capital and Left Lane Capital, which implies materially higher current revenue was underwriting that valuation. That said, the absence of disclosed current revenue figures means analysts cannot independently verify capital efficiency or unit economics — a gap that ForesightIQ flags as a key diligence item for any corp-dev or partnership conversation.

What does the composition of AnswersNow's Series B investor syndicate — HealthQuest Capital, Left Lane Capital, Owl Ventures — signal about how the company is being positioned strategically?

The syndicate blends a pure healthcare growth equity firm (HealthQuest Capital) with a consumer-internet-scale investor (Left Lane Capital) and an edtech/learning-focused fund (Owl Ventures), which suggests AnswersNow is being underwritten simultaneously as a clinical-outcomes business, a consumer subscription platform, and a tech-enabled learning service. This multi-frame investor base indicates the company is positioning itself at the intersection of healthcare services and consumer technology — a broader TAM story than pure clinical ABA — and likely complicates a clean strategic acquirer profile, since it fits healthcare services, edtech, and consumer health roll-up theses equally.

What does AnswersNow's competitive set — Roads to Recovery, NVFS, America World Adoption — reveal about where it actually faces market pressure versus where the real competitive threat originates?

The listed competitors are primarily community-based, in-person social service providers rather than direct telehealth ABA rivals, which suggests AnswersNow's most immediate competitive displacement is against legacy local providers rather than against venture-backed digital health peers. The more strategically relevant competitive threat — not fully captured in current profiling — likely comes from other VC-backed tele-ABA platforms and from large ABA provider networks that are adding telehealth capabilities; the current competitive framing may understate the intensity of competition at the payor and employer-benefit level.

What does AnswersNow's announcement of a corporate advisory board in mid-2025 signal about its near-term strategic priorities?

Launching a corporate advisory board roughly six months before closing a $40M Series B is a classic pre-raise credentialing move, designed to add domain expertise, network access, and institutional legitimacy to support both the fundraise and subsequent scaling. It signals that AnswersNow's leadership recognized gaps — likely in payor relations, enterprise sales, or regulatory navigation — that the existing executive team could not fill organically, and that the company is preparing for a more complex operating environment post-raise.

What does AnswersNow's presence at the HLTH conference to announce its Series B signal about its investor relations and business development strategy?

Choosing HLTH — one of the highest-profile health innovation conferences in the U.S. — as the venue to announce the $40M Series B indicates that AnswersNow is actively targeting visibility among health system executives, payor decision-makers, and strategic acquirers, not just the venture community. This is a business development signal as much as a PR one: the company is using the raise announcement to open doors with potential enterprise and payor partners who attend HLTH, consistent with a strategy of moving from a direct-to-consumer acquisition model toward B2B2C distribution through health plans and employers.

What does the structure of AnswersNow's leadership team — with distinct Chief Science, Chief Research, and Chief Product Officer roles — suggest about internal tensions or strategic alignment challenges?

Having separate CSO (Adam Dreyfus), Chief Research Officer (Brittany Wierzba), and Chief Product Officer (Jennifer Grasso) roles at a ~102-person company indicates a deliberate effort to keep clinical science and evidence generation organizationally distinct from commercial product development — a structure common in clinical-stage companies that want to protect research credibility while accelerating product velocity. The potential tension is that three senior leaders with overlapping scopes (science, research, product) at this company size can create coordination friction; how well CEO Jeff Beck arbitrates that tension will be a key operational risk factor as the company scales toward doubling clinical headcount.

Powered by ForesightIQ · Competitive intelligence from digital exhaust